- Home
- HSDT vs PYXS Comparison
HSDT vs PYXS Comparison
Compare HSDT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSDT | PYXS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.8M | 141.3M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HSDT | PYXS |
|---|---|---|
| Price | $2.72 | $3.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | 408.7K | ★ 848.7K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.27 | 3.03 |
| EPS | N/A | ★ N/A |
| Revenue | $6,017,000.00 | ★ $13,858,000.00 |
| Revenue This Year | $91.56 | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1057.12 | N/A |
| 52 Week Low | $1.19 | $1.03 |
| 52 Week High | $22.28 | $5.55 |
Technical Indicators
Market Signals| Indicator | HSDT | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 69.64 | 52.01 |
| Support Level | $2.68 | $2.95 |
| Resistance Level | $3.68 | $3.45 |
| Average True Range (ATR) | 0.16 | 0.32 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 97.20 | 29.86 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.